Mar 19, 2020
Dragonfly Therapeutics Completes New Investment Round
Mar 19, 2020
Dragonfly Therapeutics Announces Multi-Target Expansion of its Collaboration with Merck to Use Dragonfly's Proprietary TriNKET(TM) Platform to Develop Novel Therapeutic Candidates in the fields of Oncology, Infectious Disease, and Immune Disorders
Nov 20, 2019
Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology
Nov 13, 2019
Dragonfly Therapeutics Announces Celgene Opt-In of Third TriNKET(TM) Immunotherapy Drug Candidate
Nov 12, 2019
Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors
Aug 06, 2019
Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Pioneer to its Scientific Advisory Board
Apr 10, 2019
Both Nobel Prize Winner and World-Leading Clinician Join Dragonfly Therapeutics' Scientific Leadership Team
Nov 14, 2018
Dragonfly Therapeutics Announces Expansion of its Strategic Collaboration with Celgene, Doubling the Number of Programs and Including Targets for Solid Tumor Indications
Oct 08, 2018
Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Experts to its Scientific Advisory Board
Jan 29, 2018
Pioneer in Taking Immunotherapies Through the Clinic Joins Dragonfly Therapeutics as Chief Medical Officer
Jun 26, 2017
Dragonfly Therapeutics Appoints World Leader in NK Therapeutics as Chief Scientific Officer
Jun 12, 2017
Dragonfly Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel Natural Killer (NK) Cell-Based Immunotherapies using Dragonfly's TriNKET(TM) technology platform